| Literature DB >> 23647822 |
Douglas Marcotte1, Weike Zeng, Jean-Christophe Hus, Andres McKenzie, Cathy Hession, Ping Jin, Chris Bergeron, Alexey Lugovskoy, Istvan Enyedy, Hernan Cuervo, Deping Wang, Cédric Atmanene, Dominique Roecklin, Malgorzata Vecchi, Valérie Vivat, Joachim Kraemer, Dirk Winkler, Victor Hong, Jianhua Chao, Matvey Lukashev, Laura Silvian.
Abstract
Keap1 binds to the Nrf2 transcription factor to promote its degradation, resulting in the loss of gene products that protect against oxidative stress. While cell-active small molecules have been identified that modify cysteines in Keap1 and effect the Nrf2 dependent pathway, few act through a non-covalent mechanism. We have identified and characterized several small molecule compounds that specifically bind to the Keap1 Kelch-DC domain as measured by NMR, native mass spectrometry and X-ray crystallography. One compound upregulates Nrf2 response genes measured by a luciferase cell reporter assay. The non-covalent inhibition strategy presents a reasonable course of action to avoid toxic side-effects due to non-specific cysteine modification.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23647822 DOI: 10.1016/j.bmc.2013.04.019
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641